Changes in Hong Kong stocks | Le Méridien vaccine (06660) rose more than 17% in early trading. Personalized mRNA cervical cancer treatment vaccine is about to be clinically declared

The Zhitong Finance App learned that the Le Méridien vaccine (06660) rose more than 17% in early trading. As of press release, it had risen 12.69% to HK$1.82, with a turnover of HK$1,729,000.

According to the news, the Moderna mRNA cancer vaccine phase III clinical trial achieved landmark success, setting off the global mRNA circuit market. Le Méridien's mRNA cancer vaccine pipeline is extremely rich, accurately arranging the same mRNA melanoma vaccine as Moderna, and also lays out mRNA cervical cancer vaccine (HPV therapeutic mRNA vaccine), mRNA liver cancer vaccine (mRNA vaccine for liver cancer treatment), mRNA lung cancer vaccine (mRNA vaccine for lung cancer treatment), etc. Among them, the personalized mRNA cervical cancer treatment vaccine will soon be declared clinically.

According to Zhang Fan, vice president of Aimee Vaccines, Le Meridien has been deploying cancer vaccines for nearly ten years and is the first company in China to deploy mRNA cancer vaccines. Since 2017, the company has been deeply involved in mRNA technology platforms. It is the earliest domestic vaccine company to obtain independent patents for mRNA technology, and is also deeply involved in the two major racetracks of mRNA cancer vaccines and mRNA preventive vaccines. Aimee has now obtained clinical approvals for 14 domestic and international mRNA vaccines, making it the company that has obtained the most clinical approvals for mRNA vaccines in China. Among them, the mRNA shingles vaccine and mRNA RSV vaccine have been approved for clinical trials in China and the US.